

amendment adds no new matter. Support for the amendment can be found in the specification, *e.g.*, at page 5, lines 20-22 and Table 3, starting at page 27, respectively.

Claim 8 recites a sequence from a cancer-associated antigen; claims 9, 12, 13, 14, and 15 recite a cancer-associated antigen that is p53, CEA, MAGE, Her2/neu and PSM. This amendment adds no new matter. Support for the amendment can be found in the specification, *e.g.*, at page 7, lines 3-14 and Table 3, starting at page 27.

Claim 16 recites a pharmaceutically acceptable carrier. This amendment adds no new matter. Support for the amendment can be found in the specification, *e.g.*, at page 20, lines 3-18.

Claim 17 recite a peptide linked to a T helper peptide. This amendment adds no new matter. Support for the amendment can be found in the specification, *e.g.*, at page 16, lines 6-19.

Claim 18 recites a peptide linked to a lipid. This amendment adds no new matter. Support for the amendment can be found in the specification, *e.g.*, at page 16, line 25 through page 17, line 11.

Claim 19 recite a peptide linked to a different peptide that induces a cytotoxic T lymphocyte response. This amendment adds no new matter. Support for the amendment can be in found in the specification, *e.g.*, at page 23, lines 3-8.

Claim 20 recites a composition further comprising a liposome. This amendment adds no new matter. Support for the amendment can be in found in the specification, *e.g.*, at page 20, lines 24 through page 21, line 14.

Claim 21 recites a peptide complexed with an HLA-A2.1 molecule that is present on an antigen-presenting cell; claim 22 recites an antigen-presenting cell that is a dendritic cell. This amendment adds no new matter. Support for the amendment can be in found in the specification, *e.g.*, at page 1, lines 19-20, page 1 line 30, through page 2, line 5; and page 3, lines 8-10 (claim 21); and page 11, lines 22-24 (claim 22).


2. Restriction Requirement

In response to the restriction and species election requirements, Applicants elect Group I, which includes claim 1, now canceled, and new claims 7-22; and SEQ ID NO: 4. The claims that read on the elected species are claims 7-11 and 15-22.

The foregoing group and species elections are made with traverse as the six groups set forth by the Examiner all stem from a common concept and theory, and are thus related. As such, prosecution of the claims together would not place a substantially greater burden on the Examiner. Accordingly, Applicants respectfully request that the Examiner withdraw the Restriction Requirement.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JML
SF 1136184 v1